David L Cohn MD
Professor of Medicine
Associate Director, Denver Public Health, Denver Dept Health & Hospitals
Phone: (303) 436-7204
E-mail: dcohn@dhha.org
Address: Denver Public Health
605 Bannock Street
Denver, Colorado 80204-4507
Medical School
- University of Illinois Abraham Lincoln School of Medicine,
Chicago, Illinois - Residency
- Internal Medicine, University of Wisconsin Hospitals,
Madison, Wisconsin - Fellowship
- Infectious Diseases, University of Colorado Denver,
Denver, Colorado - Research Interests
- David Cohn is Associate Director of Denver Public Health and Professor of Medicine in the Division of Infectious Diseases at the University of Colorado Denver. He was previously Director of the Denver Metro Tuberculosis Clinic and the Denver Disease Control Service. Dr. Cohn has been active in research and treatment of HIV/AIDS since 1982, and founded the Denver Health Infectious Diseases/AIDS Clinic in 1984. He has been principal investigator of the Denver Community Program for Clinical Research on AIDS (CPCRA) since 1989, and is currently national chair of the Science Planning Committee and is a member of the CPCRA Management Team and Steering Committee. He has also been principal or co-principal investigator of AIDS/HIV surveillance in Colorado, and CDC-sponsored projects, including the Community-based Demonstration Project for HIV Prevention and Risk Reduction, Adult Spectrum of Disease, and HIV seroprevalence studies. Dr. Cohn is also a co-investigator in the CDC Tuberculosis Clinical Trials and Epidemiologic Studies Consortia.
- Dr. Cohn's major clinical research interest has been in the treatment and prevention of opportunistic infections in HIV-infected patients, and in particular mycobacterial infections (Mycobacterium tuberculosis and M. avium complex) in all persons. More recently, he has focused his research efforts on long-term effectiveness and outcomes of highly active antiretroviral therapy. Dr. Cohn was a medical officer in the Global Tuberculosis Programme at the World Health Organization (WHO), participating in studies of HIV-related tuberculosis in Africa and global drug resistance surveillance. He continues to be a WHO consultant and serves on the TB/HIV Working Group. Other recent international work includes being a faculty member for the MTCT-Plus Program, as a trainer in Kenya, and he has previously worked on projects or consulted in Uganda, Zambia, Botswana, Ethiopia, and South Africa. He has served on the Tuberculosis Committee of the Infectious Diseases Society of America and on the CDC Advisory Council for the Elimination of Tuberculosis.
Selected Publications
- Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonarytuberculosis: A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-15
- Cohn DL, O'Brien RJ. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing coutnries. Int J Tuberc Lung Dis 1998;2:16-26.
- Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA 1998;280:93-5.
- Reitmeijer CA, Wolitski RJ, Fishbein M, Corby NH, Cohn DL. Sex hustling, injection drug and non-gay identification among men who have sex with men: associations with high-risk sexual behaviors and condom use. Sex Trans Dis 1998;25:353-60.
- Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, Franchino B, Gibert CL, El-Sadr W, Hafner R, Korvick J, Ropka M, Heifets L, Clotfelter J, Munroe D, Horsburgh CR. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high dose clarithromycin. Clin Infect Dis 1999;29:125-33.
- American Thoracic Society. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161(Part 2):S221-47.
- Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, Fleming P, Dworkin MS, and the Adult and Adolescent Spectrum of Disease Group. When to begin highly active antiretorviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte count <350 cells/uL. Clin Infect Dis 2003;37:951-8.
- Cohn DL. Subclinical tuberculosis in HIV-infected patients: another challenge for the diagnosis of tuberculosis in high-burden countries? Clin Infect Dis 2005;40:1508-10.
- The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
Grants
- Name: DENVER COMMUNITY PROGRAM FOR CLINICAL RESEARCH ON AIDS (
Grant ID: 5U01AI042172-13
Grant type: NIH Grant - Name: DENVER COMMUNITY PROGRAM FOR CLINICAL RESEARCH ON AIDS (
Grant ID: 5U01AI042172-12
Grant type: NIH Grant - Name: DENVER COMMUNITY PROGRAM FOR CLINICAL RESEARCH ON AIDS (
Grant ID: 3U01AI042172-13S1
Grant type: NIH Grant